Paradise Lost:  The Neurobiology of Child Abuse and Neglect

Charles Nemeroff, M.D., Ph.D.

Introduction

Charles B. Nemeroff, M.D., Ph.D. is the Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences and Clinical Director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida. He received his MD and PhD (Neurobiology) degrees from the University of North Carolina (UNC) School of Medicine in Chapel Hill, North Carolina. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke and at Emory University before relocating to the University of Miami in 2009. He has served as President of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP) and sits on the Scientific Advisory Board and Board of Directors of the American Foundation for Suicide Prevention (AFSP) and the Anxiety and Depression Association of America (ADAA). He has received a number of research and education awards including the Kempf Award in Psychobiology, the Samuel Hibbs Award, Research Mentoring Award, Judson Marmor Award and the Vestermark Award from the American Psychiatric Association (APA), the Mood Disorders Award, Bowis Award and Dean Award from the ACP and the Julius Axelrod Award for mentoring from the ACNP. He was elected to the Institute of Medicine (now the National Academy of Medicine) of the National Academy of Sciences in 2002. He has been named Alumnus of the Year from the University of North Carolina (UNC) and from the UNC Medical School. He received the Doctorate Honoris Causa from Maimonides University in Buenos Aires in 2015. He is a member of the APA Council on Research and Chairs both the APA Research Colloquium for Young Investigators and the APA Work Group on Biomarkers and Novel Treatments. His research has focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also focused on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1000 research reports and reviews. He has served on the Mental Health Advisory Council of NIMH and the Biomedical Research Council for NASA. He is the co-editor in chief (with Alan F. Schatzberg, M.D.) of the Textbook of Psychopharmacology, published by the APA Press, now in its Fifth Edition. He is the co-editor in chief of a new journal published by Elsevier, Personalized Medicine in Psychiatry. His research is currently supported by grants from the NIH.

Learning Objectives

1. Summarize how gene effects are relevant to neurological mechanisms
2. Explain how a gene variation effects brain development and function so that the risk of a depressive episode is increased
3. Describe how early life experience alters response of adult neurogenesis and the treatment implications

Live webcast available at:  http://videos.mayo.edu/live

1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live.  Ethos will be implemented for all post presentation surveys.  Your name and e-mail are not linked to your evaluation. Identifiers are tracked separately for attendance records only.  To document your attendance, please text the code given at the presentation to 507-200-3010.  For questions, email rstpsychgr@mayo.edu.

Credit Statements

• Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 
• Mayo Clinic College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

Disclosure Summary

As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development), must ensure balance, independence, objectivity and scientific rigor in its educational activities.   Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Speaker

Charles Nemeroff, M.D., Ph.D.

Relevant financial relationship(s) with industry: 

Research/Grants:
National Institutes of Health (NIH)

Consulting (last three years):
Xhale, Takeda, Mitsubishi Tanabe Pharma Development America, Taisho Pharmaceutical Inc., Lundbeck, Prismic Pharmaceuticals, Bracket (Clintara), Total Pain Solutions (TPS), Gerson Lehrman Group (GLG) Healthcare & Biomedical Council, Fortress Biotech, Sunovion Pharmaceuticals Inc., Sumitomo Dainippon Pharma.

Stockholder:
Xhale, Celgene, Seattle Genetics, Abbvie, OPKO Health, Inc., Bracket Intermediate Holding Corp., Network Life Sciences Inc.

Scientific Advisory Boards:
American Foundation for Suicide Prevention (AFSP), Brain and Behavior Research Foundation (BBRF) (formerly named National Alliance for Research on Schizophrenia and Depression [NARSAD]), Xhale, Anxiety Disorders Association of America (ADAA), Skyland Trail, Bracket (Clintara), RiverMend Health LLC, Laureate Institute for Brain Research, Inc.

Board of Directors:
AFSP, Gratitude America, ADAA

Income sources or equity of $10,000 or more:
American Psychiatric Publishing, Xhale, Bracket (Clintara), CME Outfitters, Takeda

Patents:
Method and devices for transdermal delivery of lithium (US 6,375,990B1)Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)

 
Course Directors/Planning Committee

Brian Palmer, M.D., Michael Bostwick, M.D., Karen Grothe, Ph.D., Lois Krahn, M.D., Jarrod Leffler, Ph.D., Larissa Loukianova, M.D., Mary Machulda, Ph.D., Patricia Maus, M.D., Amber Pearson, Jeffrey Staab, M.D., Cosima Swintak, M.D., Kristin Vickers Douglas, Ph.D., Cynthia Harbeck-Weber, Ph.D., Michael Zaccariello, Ph.D., Georgina Rink

Relevant financial relationship(s) with industry:

None

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

None